This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-31. Anything still debated is marked as such rather than presented as settled.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
== Active site and mechanism of catalysis == The active site of eqolosin contains a distinctive glutamic acid and glutamine catalytic dyad which are involved in substrate binding and catalysis. These residues act as a nucleophile, with the glutamic acid serving as a general acid in the first phase of the reaction, donating a proton to the carbonyl oxygen in the peptide bond of the substrate. One or two water molecules may be involved in the reaction supplying a hydroxyl group, and the glutamic acid further donates a proton to the amide nitrogen, resulting in breakage of the peptide bond. The glutamine then returns the glutamic acid to its initial state.
== Personal life == In the early 1990s, Staley enrolled in several rehab programs, but he failed to stay clean for long. At one point, the other members of Alice in Chains flew to Los Angeles for weekly therapy at Staley's rehab. During the Dirt tour, Alice in Chains' manager, Susan Silver, hired bodyguards to keep Staley away from people who might try to pass him drugs, but he ended up relapsing on alcohol and drugs during the tour. Screaming Trees' Mark Lanegan recalled partying with Staley on tour and said that, "off stage, it was an insane, dark, drug and alcohol-fuelled frat party from start to finish, with Layne [Staley] and I raising hell, behaving like teenagers, staying up for days on end. We partook of whatever drugs came our way. Heroin, cocaine, painkillers, anything." Kurt Cobain's death in April 1994 scared Staley into temporary sobriety, but soon he was back into his addiction. Alice in Chains' managers turned down lucrative touring possibilities and kept the band off the road, hoping that would help Staley. Pearl Jam lead guitarist Mike McCready also tried to help Staley by inviting him to his side project, Mad Season. McCready had hoped that playing with sober musicians would encourage Staley. On October 29, 1996, Staley's former fiancée, Demri Lara Parrott, died of a drug overdose. Staley was placed on a 24-hour suicide watch, according to NME, which quoted a friend saying Staley was taking Parrott's death "extremely badly" and had fallen into a deep depression. Lanegan told Rolling Stone in 2002, "He never recovered from Demri's death.
== Social == Social Progress Index 2017: Thailand ranked 62 of 128 nations (1=best; 128=worst). Other ASEAN nations ranked were: Malaysia, 50; Philippines, 68; Indonesia, 79; Myanmar, 96; Cambodia, 98; and Laos, 99. Social Progress Index 2015: Social progress is the capacity of a society to meet the basic human needs of its citizens. Thailand ranked 57 of 113 nations (1=best; 133=worst). Other ASEAN states were ranked: Philippines, 64; Indonesia, 86; Cambodia, 99; Laos, 102; and Myanmar, 119. Social Progress Index 2014: Thailand ranked 59 of 132 countries State of the World's Mothers 2014: Ranked 72 of 178 countries.
==== Criticism ==== A member of the ASTM D19 (Water) Committee, Erich L. Gibbs, criticized ASTM Standard D1193, by saying "Type I water could be almost anything – water that meets some or all of the limits, part or all of the time, at the same or different points in the production process."
Sources: en.wikipedia.org
=== Packages === Tetra Classic is the name of the first, tetrahedral package, launched by Tetra Pak in 1952, with an aseptic version released in 1961 and still in use, mainly for portion-sized cream packages and children's juices. The Tetra Brik, a package in the shape of a rectangular cuboid, was launched in 1963 after a long and costly development process. An aseptic version, Tetra Brik Aseptic was launched in 1969. In terms of entities sold, it is the most popular of the Tetra Pak packages. The pillow-shaped Tetra Fino Aseptic was introduced in 1997, aiming to provide low cost and simplicity. Tetra Gemina Aseptic was introduced in 2007 as the "world’s first roll-fed gable top package with full aseptic performance". The Tetra Prisma Aseptic was launched in 1996. It has an octagonal shape with the aim of providing a more ergonomic experience. The Tetra Rex is a cuboid shaped package with a gable-top. It was launched in Sweden in 1966. Tetra Recart was launched in 2003 and is a package shaped as a rectangular cuboid that is meant to provide an alternative to previously canned foodstuffs such as vegetables, fruit and pet food. Tetra Top was launched in 1986 as a re-closable, rounded cuboid package with a plastic upper part, including opening and closure elements. The lid, molded in polyethylene in a single mold, makes it easy to open and reclose. Tetra Wedge Aseptic was developed to keep packaging material to a minimum while retaining a square surface underneath. It was introduced in 1997.
The small council decided to disregard Viserys' declaration of Rhaenyra as his heir, and conspired to crown Prince Aegon (Viserys' eldest son) as the next king of Westeros. Their precedent to justify Aegon's ascension was the Great Council of 101 AC, where Viserys was chosen over Princess Rhaenys on account of sex. His death was finally revealed to the public a week later, when the silent sisters prepared his body for a cremation ceremony traditional in the Targaryen family. Upon the streets learning of Viserys' passing, a coronation ceremony was held where the greens crowned Aegon as the new Lord of the Seven Kingdoms. Aegon's claim was rejected by a furious Rhaenyra, who had a coronation of her own set up by Daemon and the blacks. The coming struggle for power between Aegon and Rhaenyra came to be known as the Dance of the Dragons, a civil war between the greens and blacks.
==== Historical funding ==== Over the last century, the responsibility to allocate funding has shifted from the OD and Advisory Committee to the individual ICs and Congress increasingly set apart funding for particular causes. In the 1970s, Congress began to earmark funds specifically for cancer research, and in the 1980s there was a significant amount allocated for AIDS/HIV research. Funding for the NIH has often been a source of contention in Congress, serving as a proxy for the political currents of the time. During the 1980s, President Reagan repeatedly tried to cut funding for research, only to see Congress partly restore funding. The political contention over NIH funding slowed the nation's response to the AIDS epidemic; while AIDS was reported in newspaper articles from 1981, no funding was provided for research on the disease. In 1984 National Cancer Institute scientists found implications that "variants of a human cancer virus called HTLV-III are the primary cause of acquired immunodeficiency syndrome (AIDS)," a new epidemic that gripped the nation. In 1992, the NIH encompassed nearly 1 percent of the federal government's operating budget and controlled more than 50 percent of all funding for health research and 85 percent of all funding for health studies in universities. From 1993 to 2001 the NIH budget doubled. For a time, funding essentially remained flat, and for seven years after the 2008 financial crisis, the NIH budget struggled to keep up with inflation. In 1999 Congress increased the NIH's budget by $2.3 billion to $17.2 billion in 2000.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.